Country-Level Prediction of Blood Type distribution in Hemophilia A in support of FVIII consumption

Introduction Hemophilia A is an inherited bleeding disorder resulting from a lack of factor VIII (FVIII). Patients with blood type O show faster decay in their FVIII pharmacokinetics and may require higher usage of factor concentrate. Although country-level blood type distribution among Hemophilia A patients is not well characterized, its alignment with the general population may offer a useful basis for prediction. Aim Compare FVIII usage across blood types and assess whether the distribution of blood types differs between general and the hemophilia A populations. Methods Data were extracted from the WAPPS-Hemo research database for the Hemophilia A population and from an online source for the general population. FVIII pharmacokinetics and usage differences were assessed using ANOVA. Poisson log-linear regression models described cross-country counts of blood types. Congruence between blood type distributions of Hemophilia A and general populations was assessed by Likelihood Ratio Test (LRT). Results FVIII pharmacokinetics and usage was significantly different in blood type O patients. LRT comparison showed no significant difference between Hemophilia A and general populations with Poisson regression describing reasonably well the count and distribution across blood types. Conclusion Blood type O patients were found to consume more FVIII on average. Predicting blood type distributions in the Hemophilia A population is enabled by their statistical similarity to the general population, potentially supporting country-level management of FVIII accessibility. Since South and Latin American countries showed a higher blood type O prevalence, Hemophilia A patients from these populations may require a higher FVIII usage.